Abstract. In the present study, we demonstrate that ��popo�y-��popo�y-sacchar�de (LPS) �nduces the express�on of �nf�ammatory cytok�nes, �nc�ud�ng �nter�euk�n (IL)-6, IL-8, IL-1β, tumor necros�s factor (TNF)-α and monocyte chemoattractant prote�n (MCP)-1 �n BEAS-2B human bronch�a� ep�the��a� ce��s �n a doseand t�me-dependent manner. Th�s �ncrease was accompan�ed by an �ncreased act�v�ty of nuc�ear factor (NF)-κB. When the express�on of β-caten�n was ana�yzed fo��ow�ng treatment w�th LPS, the mRNA �eve� was una�tered; however, the β-caten�n prote�n �eve�s �ncreased w�th a decrease �n phosphory�at�on at the ser�ne 33/37 res�dues. Nuc�ear β-caten�n prote�n �eve�s a�so �ncreased a�ong w�th the reporter act�v�ty of a β-caten�n-respons�ve TOPF�ash vector. To e�uc�date the regu�atory ro�e of β-catenin in the LPS-induced inflammatory response of bronch�a� ep�the��a� ce��s, β-caten�n product�on was knocked down us�ng s�RNA. Our resu�ts revea�ed that β-caten�n prote�n �eve�s and TOPF�ash vector reporter act�v�ty were reduced to basa� �eve�s by s�RNA transfect�on. In th�s exper�menta� cond�t�on, NF-κB act�v�ty, measured by enzyme-��nked �mmunosorbent assay (ELISA), e�ectrophoret�c mob���ty sh�ft assay (EMSA) and an NF-κB respons�ve reporter assay, was reduced to basa� levels. Similarly, LPS-induced inflammatory cytokine express�on was reduced a�most to basa� �eve�s fo��ow�ng transfect�on w�th β-caten�n s�RNA. These resu�ts demonstrate that β-caten�n pos�t�ve�y regu�ates NF-κB act�v�ty, as we�� as the express�on of inflammatory cytokines in the inflammatory response of LPS-treated bronch�a� ep�the��a� ce��s.
Introduction
The bronch�a� ep�the��um represents the �nterface between the lungs and air and is known to induce and sustain inflammatory events in respiratory diseases through the production of inflammatory cytok�nes. Understand�ng the regu�atory mechan�sms underlying the bronchial epithelial cell inflammatory response �s �mportant for the effect�ve treatment of resp�ratory d�seases, �nc�ud�ng asthma (1) . The human bronch�a� ep�the��um �s cont�nuous�y exposed to Gram-negat�ve bacter�a of wh�ch ��po-po�ysacchar�de (LPS) �s a g�yco��p�d that const�tutes the major port�on of the outer membrane (2) . H�gh �eve�s of a�rborne (up to 1 µg/m 3 ) LPS have been reported �n a var�ety of env�ronments, and LPS as a contam�nant �n house dust �s a factor that �ncreases the sever�ty of asthma (3) . LPS a�so �nduces the express�on of inflammatory cytokines, including interleukin (IL)-8 and IL-6 in bronchial epithelial cells (4) . Among the known inflammatory response regu�ators, nuc�ear factor (NF)-κB �s the most �mpor-tant, as many genes involved in inflammation have binding sites for NF-κB �n the�r promoter reg�ons (5) .
β-caten�n �s a member of the WNT/β-caten�n pathway regu�at�ng var�ous ce��u�ar processes, �nc�ud�ng pro��ferat�on, d�fferent�at�on and deve�opment (6) . In our prev�ous study, we reported that a promoter po�ymorph�sm of β-caten�n that affects its mRNA expression level was significantly associated with the r�sk of asthma �n human subjects, suggest�ng that β-caten�n may be �nvo�ved �n the d�sease mechan�sm of asthma (7) . It �s p�aus�b�e that β-catenin may modulate the inflammatory response of the bronchial epithelium stimulated by inflammatory �nducers. In th�s study, we �nvest�gated whether β-caten�n is involved in the regulation of inflammatory cytokine express�on, as we�� as NF-κB act�v�ty �n BEAS-2B human bronch�a� ep�the��a� ce��s treated w�th LPS. serum, 100 µg/ml streptomycin and 100 U/ml penicillin at 37˚C �n 5% CO 2 . The ce��s were treated w�th 0.001 to 10 µg/m� of LPS (Sigma-Aldrich, St. Louis, MI, USA) to induce an inflammatory response. Untreated ce��s were used as contro�s.
Real-time reverse transcription polymerase chain reaction (PCR) of inflammatory cytokines.
The ce��s were cu�tured �n 12-we�� p�ates and tota� RNA was extracted us�ng an RNeasy k�t (Q�agen, H��den, Germany). Tota� RNA was reverse transcr�bed us�ng a cDNA Reverse Transcr�pt�on k�t (App��ed Biosystems Inc., Foster City, CA, USA). Briefly, the reaction was performed in a final volume of 20 µl that included 100 mM dNTP, random pr�mers, Mu�t�Scr�be™ Reverse Transcr�ptase, RNase �nh�b�tor and 1 µg tota� RNA. The react�on m�xtures were heated at 25˚C for 10 min, 37˚C for 120 min and 85˚C for 5 sec. Rea�-t�me PCR was performed us�ng a StepOne PCR System (Applied Biosystems, Inc.) in triplicate in a final volume of 20 µl that �nc�uded TaqMan gene express�on master m�x, an opt�m�zed concentrat�on of each pr�mer, 250 nM TaqMan probe and 2.0 µ� cDNA react�on m�xture. The react�on m�xtures were pre-heated at 95˚C for 10 min to activate the enzyme, and then subjected to 40 cycles of melting at 95˚C for 15 sec and annealing/extension at 60˚C for 1 min. The real-time PCR efficiencies were approximately 100%. The assay-on-demand gene express�on products (App��ed B�osystems, Inc.) were used to eva�uate the mRNA express�on �eve�s of IL-6 (Hs00174131_m1), IL-8 (Hs99999034_m1), IL1-β (Hs01555410_m1), tumor necros�s factor (TNF)-α (Hs01113624_g1), monocyte chemoattractant prote�n (MCP)-1 (Hs00234140_m1), β-caten�n (Hs00170025_m1) and 18S rRNA (Hs99999901_s1). The 18S rRNA was used as an �nterna� contro�. For each samp�e, the mRNA �eve�s were norma��zed aga�nst the 18S rRNA �eve� and the rat�os of norma��zed mRNA to the untreated contro� samp�e were determ�ned us�ng the comparat�ve Ct method, as prev�ous�y descr�bed (8) .
Enzyme-linked immunosorbent assay (ELISA) to measure NF-κB DNA binding activity. Nuc�ear prote�n extracts were prepared from the LPS-treated ce��s us�ng a nuc�ear extract k�t (Act�ve Mot�f, Car�sbad, CA, USA) and ana�yzed to determ�ne the prote�n concentrat�on us�ng a BCA prote�n assay k�t (P�erce, Rockford, IL, USA). The b�nd�ng act�v�ty of NF-κB to �ts target DNA sequence (5'-GGGACTTTCC-3') was measured us�ng a TransAM NF-κB ELISA kit (Active Motif). Briefly, 10 µg of prote�n �n the nuc�ear prote�n extracts were added to 96-we�� p�ate we��s coated w�th o��gonuc�eot�de conta�n�ng the target DNA sequence. Fo��ow�ng �ncubat�on and wash�ng, an ant�-NF-κB ant�body was added to the we��s fo��owed by a horserad�sh perox�dase-conjugated secondary ant�body.
Electrophoretic mobility shift assay (EMSA) to determine NF-κB activity. Pr�mer sets conta�n�ng an NF-κB target sequence cons�st�ng of a forward pr�mer, 5'-AGTTGAGGGGA CTTTCCCAGGC-3' and a comp�ementary reverse pr�mer, 5'-GCCTGGGAAAGTCCCCTCAACT-3' were b�ot�n-�abe�ed at the�r 5' end. The forward and reverse pr�mers were annea�ed by heating at 95˚C for 5 min and cooled slowly to room temperature. Subsequent�y, 10 ng of annea�ed pr�mer, 8 µg of prote�n �n the nuc�ear prote�n extract, and 1 µg of po�y d(I-C) were incubated at 15˚C for 30 min in a final volume of 10 µl. For compet�t�on exper�ments, 660 ng of un�abe�ed NK-κB probe was added. The react�on m�xtures were separated by 6% non-denatur�ng po�yacry�am�de ge� e�ectrophores�s at 120 V �n Tr�s-Borate-EDTA buffer, and e�ectrotransferred to a ny�on membrane at 300 mA for 30 m�n. The �ocat�on of the pr�mer-prote�n comp�exes was v�sua��zed by �ncubat�ng the membrane w�th horserad�sh perox�dase-conjugated streptav�d�n fo��owed by enhanced chem��um�nescence detect�on.
Reporter assay for NF-κB and β-catenin. For NF-κB reporter assay, the ce��s were co-transfected w�th a pGL 4.32 vector (Promega, Mad�son, WI, USA) conta�n�ng the NF-κB response element linked to a firefly luciferase reporter gene and a 1:50 rat�o of pGL 4.17 vector (Promega) conta�n�ng Renilla �uc�f-erase reporter gene. Ce��s were harvested 24 h after transfect�on, and �uc�ferase act�v�ty was measured us�ng a Dua�-Luc�ferase Reporter Assay System (Promega). For each assay, firefly luciferase act�v�ty was norma��zed to the Renilla �uc�ferase act�v�ty to control for variations in transfection efficiency.
For the β-caten�n reporter assay, the ce��s were co-transfected w�th a TOPF�ash vector (M����pore, B���er�ca, MA, USA) conta�n�ng the β-caten�n response e�ement ��nked to a firefly luciferase reporter gene and a 1:50 ratio of pGL 4.17 vector conta�n�ng Renilla �uc�ferase reporter gene. Luc�ferase act�v�ty was measured as descr�bed above.
Western blot analysis of total β-catenin. The ce��s were �ysed w�th �ce-co�d RIPA buffer conta�n�ng 25 mM Tr�s-HC� (pH 7.6), 150 mM NaC�, 1% Non�det P-40, 1% sod�um deoxycho�ate, 0.1% SDS and protease �nh�b�tor cockta�� (S�gma-A�dr�ch). Tota� ce�� �ysates were obta�ned after remov�ng the �nso�ub�e materials by centrifugation at 20,000 x g for 20 min at 4˚C. The prote�n concentrat�ons were determ�ned us�ng a BCA prote�n assay k�t (P�erce), and 50 µg prote�n were separated by 12% po�yacry�am�de ge� e�ectrophores�s and e�ectrotrans-ferred onto n�troce��u�ose membranes at 150 mA for 1.5 h. The membranes were then b�ocked for 3 h at room temperature w�th phosphate-buffered sa��ne conta�n�ng 5% sk�m m��k and 0.1% Tween-20 and �ncubated w�th a 1:1,000-d��ut�on of ant�-β-caten�n ant�body (BD B�osc�ences, San Jose, CA, USA) overn�ght at 4˚C, and subsequently incubated with a 1:1,000-dilution of horserad�sh perox�dase-conjugated secondary ant�body (Ce�� S�gna��ng, Bever�y, MA, USA) for 2 h at room temperature. Perox�dase act�v�ty was v�sua��zed us�ng an ECL k�t (B�o-Rad Laborator�es Inc., Hercu�es, CA, USA). Ant�-β-act�n ant�body (Santa Cruz B�otechno�ogy Inc., Santa Cruz, CA, USA) was used as the �oad�ng contro� for tota� ce�� �ysates.
Western blot analysis of nuclear β-catenin. The ce��s were harvested and then nuc�ear fract�ons were co��ected us�ng a nuc�ear extract k�t (Act�ve Mot�f). Prote�n concentrat�ons �n each fract�on were determ�ned us�ng a BCA prote�n assay k�t (P�erce). Prote�n (15 µg) was separated us�ng a 12% po�y-acry�am�de ge� e�ectrophores�s and ana�yzed by western b�ot ana�ys�s us�ng an ant�-β-caten�n ant�body fo��owed by horserad�sh perox�dase-conjugated ant�-mouse secondary ant�body.. Ant�-TATA box b�nd�ng prote�n (TBP) was used as the �oad�ng contro� for nuc�ear prote�n extracts.
Transfection with small interfering RNA (siRNA). The ce��s were seeded �n 12-we�� p�ates at a dens�ty of 5x10 5 ce��s/we�� and then transfected w�th 50 nM of contro� s�RNA or β-caten�n s�RNA (Santa Cruz B�otechno�ogy, Inc.) us�ng L�pofectam�ne RNA�MAX transfect�on reagent (Inv�trogen, Car�sbad, CA, USA). After 18 h, the ce��s were treated w�th LPS (0.001 to 10 µg/ml) to induce an inflammatory response. Untreated cells were used as contro�s.
Statistical analysis. A�� data are expressed as the means ± standard dev�at�on from at �east 3 rep��cate exper�ments. Stat�st�ca��y s�gn�f�cant d�fferences between the treated and untreated samp�es were detected us�ng unpa�red t-tests. A P-va�ue of <0.05 was cons�dered stat�st�ca��y s�gn�f�cant. A�� ana�yses were performed us�ng SPSS vers�on 18.0 software (SPSS Inc., Ch�cago, IL, USA).
Results

LPS induces inflammatory cytokine expression in BEAS-2B human bronchial epithelial cells in a dose-and time-dependent manner.
When the BEAS-2B human bronch�a� ep�the��a� ce��s were treated w�th var�ous concentrat�ons of LPS (0.001 to 10 µg/ml), the expression levels of inflammatory cytokines, �nc�ud�ng IL-6, IL-8, IL-1β, TNF-α and MCP-1 �ncreased �n a dose-dependent manner (F�g. 1). It was found that LPS �nduced significantly high levels of inflammatory cytokine expression at a dose of 0.1 µg/m�, and a�� subsequent exper�ments were conducted at th�s LPS concentrat�on. Subsequent�y, when the ce��s were treated w�th 0.1 µg/m� LPS for var�ous per�ods of time, the inflammatory cytokine expression began to increase 0.5 to 1 h fo��ow�ng treatment w�th LPS and subsequent�y �ncreased �n a t�me-dependent manner for up to 3 h. TNF-α, however, showed �ts max�mum express�on 2 h fo��ow�ng treatment w�th LPS, and decreased 3 h fo��ow�ng treatment w�th LPS (F�g. 2).
LPS induces NF-κB activity in BEAS-2B human bronchial epithelial cells.
The act�v�ty of NF-κB, the major inflammatory transcr�pt�on factor, was exam�ned �n the ce��s treated w�th 0.1 µg/m� LPS for var�ous per�ods of t�me. The b�nd�ng act�v�ty of NF-κB to �ts target DNA sequence was �nvest�gated by both ELISA (F�g. 3A) and EMSA (F�g. 3B) exper�ments. The resu�ts from the ELISA and EMSA exper�ments were s�m��ar �n that NF-κB was found to b�nd �ts target DNA sequence fo��ow�ng treatment w�th 0.5 h LPS (F�g. 3A and B). In the EMSA exper�-ments, the sh�fted e�ectrophoret�c mob���ty patterns of the �abe�ed NF-κB probe were �nh�b�ted by excess amounts of un�abe�ed NF-κB probe, show�ng that the resu�ts were not med�ated by non-specific binding (Fig. 3B, lanes 3-7 vs. lane 8) . The NF-κB reporter assay was conducted us�ng a pGL4.32 vector, wh�ch has a �uc�ferase gene ��ked to an NF-κB response e�ement. The resu�ts �nd�cated that NF-κB-dr�ven �uc�ferase express�on �ncreased at approx�mate�y 1 h fo��ow�ng treatment w�th LPS (F�g. 3C).
LPS upregulates the level of β-catenin protein in total cell
lysates and nuclear extracts. When the ce��s were treated w�th 0.1 µg/m� LPS for var�ous per�ods of t�me, the mRNA �eve� of β-catenin was not significantly altered (Fig. 4A) . However, the β-caten�n prote�n �eve� �n the tota� ce�� �ysates was upregu�ated 0.5 h fo��ow�ng treatment w�th LPS, wh�ch was accompan�ed by the reduced phosphory�at�on of β-caten�n at ser�ne 33/37 res�dues (F�g. 4B). The nuc�ear β-caten�n prote�n �eve� was a�so upregu�ated 0.5 h fo��ow�ng treatment w�th LPS (F�g. 4C). A reporter assay was conducted us�ng a TOPF�ash vector, wh�ch has a �uc�ferase gene ��ked to a β-caten�n response e�ement (F�g. 4D).
The resu�ts revea�ed that LPS �nduced β-caten�n-dr�ven �uc�f-erase express�on.
Knockdown of β-catenin results in a decrease in NF-κB activity in LPS-treated cells.
In the knockdown exper�ments, the ce��s were transfected w�th contro� s�RNA or β-caten�n s�RNA and treated w�th LPS �n order to �nduce NF-κB act�v�ty. Both the β-caten�n prote�n �eve� and �uc�ferase express�on by a β-caten�n respons�ve promoter, wh�ch were upregu�ated fo��ow�ng treatment w�th LPS, were decreased by β-caten�n s�RNA transfect�on compared w�th contro� s�RNA transfect�on [F�g. 5A (�ane 3 vs. �ane 4) and B], c�ear�y show�ng that the s�RNA-med�ated knockdown of β-caten�n express�on had occurred. In th�s exper�menta� cond�t�on, NF-κB act�v�ty was measured by ELISA (F�g. 5C), EMSA (F�g. 5D) and reporter assays (F�g. 5E). The target DNA b�nd�ng act�v�ty of NF-κB measured by ELISA was significantly decreased by β-caten�n s�RNA compared w�th contro� s�RNA �n the LPS-treated ce��s (F�g. 5C), and the EMSA resu�ts showed �dent�ca� patterns (F�g. 5D, �ane 3 vs. �ane 4). The sh�fted e�ectrophoret�c mob���ty patterns of the �abe�ed NF-κB probe were �nh�b�ted by excess un�abe�ed NF-κB probe, show�ng that the resu�ts were not mediated by non-specific binding (Fig. 5D, lanes 5-8) .
Luc�ferase express�on med�ated by a promoter conta�n�ng the NF-κB target sequence was also significantly decreased by β-caten�n s�RNA compared w�th contro� s�RNA �n the LPS-treated ce��s (F�g. 5E).
Knockdown of β-catenin results in decreased inflammatory cytokine expression in LPS-treated cells.
The ce��s were transfected w�th contro� s�RNA or β-caten�n s�RNA and treated w�th LPS for the induction of inflammatory cytokine expression. The exper�menta� resu�ts demonstrated that the express�on �eve�s of IL-6, IL-8, IL-1β, TNF-α and MCP-1, wh�ch were �nduced by treatment with LPS, were all significantly decreased by β-caten�n s�RNA transfect�on compared w�th contro� s�RNA transfect�on �n the LPS-treated ce��s (F�g. 6).
Discussion
Our �nterest �n β-catenin as a modulator of bronchial inflammat�on was prompted by a prev�ous study report�ng that a genet�c po�ymorph�sm of β-catenin was significantly asso- c�ated w�th the r�sk of asthma �n human subjects (7) . Unt�� now, however, the ro�e of β-caten�n has not been e�uc�dated in the inflammatory response of bronchial epithelial cells. In the present study, we demonstrate that β-caten�n p�ays a role in the regulation of the inflammatory response of human bronch�a� ep�the��a� ce��s treated w�th LPS.
Our results revealed that LPS induced inflammatory cytokine express�on �n bronch�a� ep�the��a� ce��s �n a dose-and t�me-dependent manner (F�gs. 1 and 2), wh�ch was accompan�ed by the �nduct�on of NF-κB act�v�ty. NF-κB act�v�ty was measured us�ng 3 d�fferent methods, ELISA, EMSA, and a reporter assay (F�g. 3). When the express�on of β-caten�n was ana�yzed �n the LPS-treated bronch�a� ep�the��a� ce��s, the mRNA �eve�s were not a�tered (F�g. 4A). However, the β-caten�n prote�n �eve�s �n the tota� ce�� �ysates were �ncreased at 0.5 h fo��ow�ng treatment w�th LPS w�th a s�mu�taneous reduct�on �n the phosphory�at�on �eve� at the ser�ne 33/37 res�dues (F�g. 4B). Nuc�ear β-caten�n �eve�s were a�so �ncreased 0.5 h fo��ow�ng treatment w�th LPS (F�g. 4C). β-caten�n �s a member of the WNT/β-caten�n pathway that has been reported to regu�ate ce��u�ar processes, �nc�ud�ng pro��ferat�on, d�fferent�at�on and deve�opment (6) . The �eve� of β-caten�n �s post-trans�at�ona��y regu�ated �n the WNT/β-caten�n pathway. In �ts �nact�ve state, β-caten�n prote�n �s degraded by a destruct�on comp�ex composed of AXIN, g�ycogen synthase k�nase (GSK)3β and adenomatous po�ypos�s co�� (APC). GSK3β phosphory�ates β-caten�n at ser�ne 33 and 37 res�dues creat�ng a b�nd�ng s�te for E3 ub�qu�t�n for ub�qu�t�nat�on and proteo�yt�c degradat�on. When the WNT/β-caten�n pathway �s act�vated, the AXIN-GSK3β-APC comp�ex �s d�srupted and GSK3β �s �nact�vated, resu�t�ng �n the dephosphory�at�on and stab���zat�on of β-caten�n fo��owed by �ts nuc�ear trans�ocat�on (9, 10) . The exper�menta� resu�ts presented �n th�s study c�ear�y �nd�cate that LPS �nduced the dephosphory�at�on, stab���zat�on and nuc�ear trans�ocat�on of β-caten�n, as we�� as the reporter act�v�ty of the β-caten�n-respons�ve TOPF�ash vector �n the bronch�a� ep�the-��a� ce��s (F�g. 4).
To e�uc�date the ro�e of β-caten�n �n the LPS-�nduced inflammatory response of bronchial epithelial cells, β-caten�n was knocked down us�ng s�RNA. The resu�ts revea�ed that the β-caten�n prote�n �eve�, as we�� as �ts act�v�ty as a transcr�pt�ona� act�vator as measured by the β-caten�n-respons�ve TOPF�ash vector reporter act�v�ty, was reduced to basa� �eve�s by β-caten�n s�RNA transfect�on (F�g. 5A and B). In th�s exper�menta� cond�-t�on, NF-κB act�v�ty was measured us�ng 3 d�fferent methods, ELISA, EMSA and reporter assays; as shown by a�� 3 methods, �ts act�v�ty was reduced to basa� �eve�s (F�g. 5C-E). S�m��ar�y, LPS-induced inflammatory cytokine expression was reduced to a�most basa� �eve�s by β-caten�n s�RNA transfect�on (F�g. 6).
These exper�menta� data c�ear�y demonstrate that β-caten�n �s �nvo�ved �n the act�vat�on of NF-κB, as we�� as �n the �nduc-tion of inflammatory cytokine expression in the inflammatory response of LPS-treated bronch�a� ep�the��a� ce��s.
A number of stud�es have reported a major ro�e for NF-κB in the inflammation of bronchial epithelial cells stimulated by tox�c and pathogen�c agents, �nc�ud�ng c�garette smoke extract, d�ese� exhaust part�c�es, wood dust, resp�ratory syncyt�a� v�rus, rh�nov�ruses, Bordetella pertussis and house dust m�tes (11) (12) (13) (14) (15) (16) . The exaggerated act�vat�on of NF-κB has been found �n bronch�a� ep�the��a� ce��s w�th a mutat�on character�st�c of cyst�c f�bros�s, a genet�c d�sease character�zed by chron�c a�rway inflammation (17) . Erythromycin, which improves the clinical symptoms of pat�ents w�th bronch�o��t�s, has been reported to suppress the act�vat�on of NF-κB and IL-8 product�on �n human bronch�a� ep�the��a� ce��s (18) . A�� the above stud�es have suggested that the regu�at�on of NF-κB act�v�ty has cruc�a� �mportance for the effect�ve treatment of resp�ratory d�seases involving bronchial inflammation.
Unt�� now, β-caten�n has been ma�n�y assoc�ated w�th cancer (19) , and mutat�ons �n the β-caten�n gene have been common�y observed �n endometr�o�d ovar�an cancer, hepatob�astoma, W��ms' k�dney tumors and some co�orecta� cancers (20) . Cons�der�ng the ro�e of β-caten�n �n var�ous ce��u�ar processes of d�fferent�at�on and deve�opment, however, β-caten�n may a�so be �nvo�ved �n chron�c �nf�ammatory d�seases (6) . Our prev�ous study reported that genet�c po�ymor-ph�sms of β-caten�n are assoc�ated w�th asthma (7); however, further stud�es are requ�red to e�uc�date the ro�e of β-caten�n in the regulation of inflammation. A few studies have reported controvers�a� ro�es of β-catenin as a regulator of inflammation. Duan et al reported that β-caten�n negat�ve�y regu�ated the inflammatory response induced by pathogenic Gram-negative bacter�a. They reported that Salmonella typhimurium st�mu-�ated the degradat�on of β-caten�n and �ncreased the express�on �eve�s of IL-6 and TNF-α �n a mouse mode� and �n co�on�c ep�the��a� ce��s (21) . On the contrary, K�m et al reported that β-catenin positively regulated the inflammatory response to LPS. They reported that LPS �nduced β-caten�n accumu�a-t�on and nuc�ear trans�ocat�on fo��owed by the �nduct�on of NADPH ox�dase �n RAW 264.7 macrophages and mur�ne bone-marrow-der�ved macrophages (22) . We have prev�ous�y demonstrated that β-catenin positively regulates inflammatory cytok�ne express�on �n THP-1 human monocyt�c ce��s st�mu-�ated by the Der p 1 house dust m�te a��ergen (23) . Desp�te d�screpanc�es, these data suggest a ro�e of β-caten�n �n the regulation of the inflammatory response.
In th�s study, we prov�de c�ear exper�menta� ev�dence that β-caten�n pos�t�ve�y regu�ates NF-κB activity, as well as inflammatory cytok�ne express�on �n bronch�a� ep�the��a� ce��s treated w�th LPS. The resu�ts of th�s study suggest that β-caten�n may be a target for the modulation of bronchial inflammation, even though further stud�es are requ�red to e�uc�date the mo�ecu�ar mechan�sms �nvo�ved and to prov�de c��n�ca� ev�dence.
